Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Oct 16, 2013
SEATTLE, Oct. 16, 2013 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company will release 2013 third quarter financial results after the close of trading on Tuesday, November 5, 2013. Company management will hos...
Oct 1, 2013
SEATTLE, Oct. 1, 2013 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG) and Fluidigm Corporation (Nasdaq:FLDM) have agreed to settle lawsuits filed by Fluidigm in the United States and Singapore. In the U.S. case, Fluidigm charged NanoString with false advertising, unfair competition, and unlawful trade practices based on a comparison...
Sep 16, 2013
Authors concluded that PAM50 Gene Signature was better than Oncotype DX® and IHC4 Assays at Categorizing Patients into Low and High Risk for Late Distant Recurrence SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc., (NASDAQ: NSTG) a provider of life science ...
Sep 9, 2013
Prosigna Assay on the nCounter® Dx Analysis System Provides Compelling Clinical Data,Clear Patient Report, and Decentralized Testing in Qualified Labs SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for tr...
Sep 5, 2013
SEATTLE and SAN JOSE, Calif., Sept. 5, 2013 /PRNewswire/ -- NanoString Technologies, Inc. (NASDAQ: NSTG), a provider of life science tools for translational research and molecular diagnostic products, and BD Biosciences, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a colla...
Aug 26, 2013
SEATTLE, Aug. 26, 2013 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), today announced that it will be participating in two upcoming investor conferences. NanoString Technologies management is scheduled to participate in the 2013 Morgan Stanley Global Healthcare Conference in New York on Monday, September 9, 2013 at 11:45 a...
Aug 6, 2013
SEATTLE, Aug. 6, 2013 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today reported financial results for the three and six months ended June 30, 2013. Highlights of the second quarter include: Total revenue of $7.2...
Jul 29, 2013
nCounter Elements General Purpose Reagents are First NanoString Product with Open Architecture to Support Independent Development of Diagnostic Tests SEATTLE & HOUSTON--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ: NSTG), a provider of life science tools for translational...
Jul 17, 2013
SEATTLE, July 17, 2013 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company will release 2013 second quarter financial results after the close of trading on Tuesday, August 6, 2013. Company management will host...
Jul 2, 2013
Authors Conclude that PAM50-based Assay Provides More Prognostic Information than Oncotype DX ® with Better Differentiation of Intermediate and High Risk Groups SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ: NSTG), a provider of life science tools for transla...
Jun 25, 2013
SEATTLE--(BUSINESS WIRE)--June 25, 2013-- NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced the pricing of its initial public offering of 5.4 million shares of common stock at a price to the public of $10.00 per share. In addition, the Company has granted th...
Jun 3, 2013
SEATTLE and CHICAGO | June 3, 2013 — NanoString Technologies, Inc., a privately held provider of life science tools for translational research and molecular diagnostic products, today announced new results from the combined data analysis of the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG-8) and Arimidex, Tamoxifen, Alone or in Com...
May 20, 2013
SEATTLE | May 20, 2013 – NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced that it has filed ...
May 15, 2013
SEATTLE and CHICAGO | May 15, 2013 — NanoString Technologies, Inc., a privately held provider of life science tools for translational research and molecular diagnostic products, today a...
May 2, 2013
Positive Results from Two Studies of the PAM50-Based In Vitro Diagnostic Assay will be Presented at the Annual IMPAKT Breast Cancer Conference SEATTLE and BRUSSELS, BELGIUM | May 2, 2013 ...
= add release to Briefcase